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Abstract
Introduction: Krabbe disease (KD) is an autosomal recessive
disorder caused by mutations in the galactocerebrosidase (GALC)
gene resulting in neuro-inflammation and defective myelination
in the central and peripheral nervous systems. Most infantile
patients present with clinical features before six months of age and
die before two years of age. The only treatment available for presymptomatic or mildly affected individuals is hematopoietic stem
cell transplantation (HSCT). In the animal models, combining
bone marrow transplantation (BMT) with gene therapy has shown
the best results in disease outcome. In this study, we examine the
outcome of gene therapy alone.
Methods: Twitcher (twi) mice used in the study, have a W339X mutation in the GALC gene.
Genotype identification of the mice was performed shortly after birth or post-natal day 1 (PND1),
using polymerase chain reaction on the toe clips followed by restriction enzyme digestion and
electrophoresis. Eight or nine-day-old affected mice were used for gene therapy treatment alone or
combined with BMT. While iv injection of 4 × 1013 gc/kg of body weight of viral vector was used
originally, different viral titers were also used without BMT to evaluate their outcomes.
Results: When the standard viral dose was increased four- and ten-fold (4X and 10X) without
BMT, the lifespans were increased significantly. Without BMT the affected mice were fertile, had
the same weight and appearance as wild type mice and had normal strength and gait. The brains
showed no staining for CD68, a marker for activated microglia/macrophages, and less astrogliosis
than untreated twi mice.
Conclusion: Our results demonstrate that, it may be possible to treat human KD patients with high
dose AAVrh10 without blood stem cell transplantation which would eliminate the side effects of
HSCT.

Introduction
Globoid cell leukodystrophy (GLD) or Krabbe disease
(KD) is a lysosomal disorder caused by the deficiency
of galactocerebrosidase (GALC) activity.1 The disease is
inherited in an autosomal recessive manner and presents
in the most severe infantile form by 6 months of age,
followed by death usually by 2 years of age.2 While the
infantile form of the disease is most common, later onset
and adult patients with KD are also diagnosed. In the
absence of GALC activity not only galactosylceramide
(galcer), an important component of myelin, cannot be
degraded but galactosylsphingosine or psychosine also
accumulates to a toxic level.3-5
There are several animal models for this disease,
including mouse, dog, and monkey models that are
being used for the treatment trials.6-8 Twitcher (twi)

mouse, the murine model of KD, has been extensively
used to understand the pathogenesis of this disease and
in many treatment trials.9 This has resulted in various
outcomes in improving the myelination process and
extension of life. However, none of these approaches has
resulted in a complete correction of the clinical features
and pathological aspects of the disease. For complete
correction of the disease, adequate GALC activity needs
to be delivered to the CNS and PNS. Gene therapy seems
the most promising in addressing this need, but the blood
brain barrier (BBB) remains an issue.10-15
Hematopoietic stem cell transplantation (HSCT) is
currently the “standard of care” for human patients.16,17
Besides providing some GALC enzyme to different CNS
cell types, it may play an anti-inflammatory role. GALCexpressing macrophages from transplanted HSCs play
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pivotal role in cleaning up the undegraded myelin debris
and content of the globoid cells.18 In animal models
of the disease, BMT has shown a synergistic effect
when combined with other treatment strategies.9 The
mechanism of such synergistic effect has also been the
subject of several studies.19,20
While the lack of GALC activity in the CNS and PNS
is the main cause of the disease, inflammation within the
nervous system is also a characteristic of KD.21 We have
previously highlighted the anti-inflammatory role of BMT
in murine model of this disease.22 In the current article,
we assess the abilities of bone marrow (BM) cells and
AAVrh10-mGALC to deliver GALC activity to critical
tissues and their ability to prevent or decrease neuroinflammation and extend the lives of the treated mice. An
increase of GALC activity in brain following BMT was
originally reported by several authors.23-26 However, the
anti-inflammatory role of BM cells in the treatment of the
KD may have been overstated in past decades while their
GALC-supplying capacity has been understated.20,27,28
Following our recent publication on the effect of viral dose
and timing of treatment of twi mice,29 we were interested
in exploring the effect of high viral dose alone in their
treatment. The results demonstrate that early gene therapy
at a sufficiently high dose can supply high GALC activity
to the brain and other tissues and possibly prevent neuroinflammation before it has started. In the current paper,
besides iv injection of our standard viral dose (4 × 1013 gc/
kg of body weight, called 1X dose), we have increased viral
dose four times (4X = 1.6 × 1014 gc/kg of body weight)
and ten times (10X = 4 × 1014 gc/kg of body weight) alone
or combined with BMT. The results could indicate that
iv injection of AAVrh10-mGALC alone supplied at high
dose at an early time point could be successful in treating
human patients without the need for HSCT.
Materials and Methods
Animal procedures
All studies in mice were completed in accordance with
approved protocols from the Institutional Animal Care
and Use Committee (IACUC) at Jefferson Medical College.
Twi mice used in the study were originally obtained from
the Jackson Laboratory. These mice are in the C57BL/6
background and have a W339X mutation in the GALC
gene. Genotype identification of the mice was performed
immediately after birth or on post-natal day 1 (PND1)
using polymerase chain reaction (PCR) as previously
described.12,30 Toe clips were used for DNA extraction
and genotyping. PCR products were digested with EcoRV
restriction enzyme and analyzed by electrophoresis on
2.5% MetaPhor agarose gel (Lonza Inc. Allendale, NJ,
USA). Treated mice were monitored daily for the first
week after the treatment was started and any abnormal
signs related to the procedure was noted. Body weight
was recorded weekly throughout their lives. Treated mice
were allowed to survive as long as humanely possible or
136
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sacrificed at different time points for analysis. If deemed
moribund (inactive and with unexpected weight loss) the
mice were euthanatized by carbon dioxide and the age was
recorded.
Generation of AAVrh10-mGALC vector
Construction of the AAVrh10-mGALC vector was
previously reported.13 Briefly, pCB7plasmid, which is an
enhanced version of AAV2 vector, was received from the
Institute for Human Gene Therapy at the University of
Pennsylvania. Murine GALC cDNA was cloned into EcoRI
site of this plasmid, downstream from the human CMVenhancer/chicken β-actin hybrid promoter. The integrity
of the ITRs was confirmed by sequencing and restriction
enzyme analysis using SmaI and NcoI. The functionality of
the construct was verified by in vitro cell transfection and
measurement of GALC enzyme activity. Viral packaging
and purification of the product were accomplished by the
Institute for Human Gene Therapy and the vector was
called AAVrh10-mGALC.12,13 Viral titer was determined
by PCR of the simian virus 40 poly(A) sequence.31,32 The
viral titer of the vector batch of AAVrh10-mGALC in use
is 6×1013 genomic equivalents/mL.
Viral delivery
Viral injections were carried out on a light box to facilitate
visualizing the tail vein. The young mice were cryoanesthetized on ice before the injections. Iv injection was
done through the tail vein using a 28G insulin syringe.28
The success of injection was verified by noting blanching
of the vein.12 After the injection, pups were warmed and
returned to their cage. Mice that died within a few days
of the injection (less than 10%) were not included in the
study.
Bone marrow transplantation (BMT)
The methodology for BM preparation and BMT was
previously described.28 Briefly, BMT recipient mice were
myelo-suppressed using busulfan (Sigma-Aldrich, St.
Louis, MO, USA). A 3 mg/mL solution of busulfan was
prepared by initially dissolving it in dimethyl sulfoxide
(Sigma-Aldrich) and adding sterile phosphate-buffered
saline to bring the final concentration to 30%. Eight or
nine-day-old affected mice were weighed, and 30 mg/
kg of body weight of the busulfan solution was injected
intraperitoneally (ip). BM cells from the donor mice were
obtained by flushing tibiae and femora using ice-cold
Hepes buffered Hanks’ balanced salt solution (Mediatech,
Manassas, VA, USA). The cells were counted, centrifuged,
and resuspended in Dulbecco's modified Eagle's medium
(Sigma-Aldrich). Twenty-four hours after busulfan
injection, mice received an ip injection of 3–4 × 107 BM
cells in a total volume of 0.2 mL. For at least two weeks
after BMT, mice were provided with drinking water
containing 500 μg/mL Neomycin (Sigma-Aldrich). Mice
that received BMT and died less than PND30 were not
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included in these studies. Initially BM cells from noncarrier donors were used, but in some later studies BM
cells from carrier mice were also used.
Preparation of BM cells for GALC activity test
To harvest BM cells from treated or untreated twi mice,
wild type and heterozygote mice, cell isolation steps for
BMT were followed as previously described.28 Briefly, BM
cells were harvested by flushing tibiae and femora using
ice-cold Hepes buffered Hanks’ balanced salt solution
(Mediatech, Manassas, VA, USA). 28-G sterile needle were
used for rinsing the bones. Collected cells were filtered
through a 70-µm nylon web to extract the maximum
quantity of BM cells, rinsed repeatedly with phosphate
buffered saline (PBS) (Sigma-Aldrich), centrifuged and
resuspended in 1 mL of Dulbecco's modified Eagle's
medium.
Preparation of BM-derived monocytes/macrophages
BM cells were prepared as described above. To differentiate
these cells towards monocytes the protocol proposed by
Wagner et al33 was followed. Harvested cells were counted
and seeded on 6-well ultra-low-attachment surface plates
to prevent permanent adhesion to the bottom of the
plate on a concentration of 106 cells per ml with up to 6
ml per well. Plates were supplemented with 20 ng/mL
macrophage colony stimulating factor (M-CSF) (SigmaAldrich) to promote cell differentiation. The 6-well plates
were incubated at 37°C and 5% carbon dioxide for 5 days
and observed daily. After 5 days, 60%-80% of the cells
were expected to be differentiated to monocytes.
Harvesting the cultured BM cells and tail vein injection
Cells were harvested in ice-cold PBS containing 0.5%
bovine serum albumin (BSA) (Sigma-Aldrich) and 2-mM
EDTA (Sigma-Aldrich). kept in 4°C by gentle pipetting
and detaching with cold harvesting solution. Cells were
counted and suspended in 0.9% NaCl at a concentration
of 10 × 106/mL.
Preparation of indomethacin solution
Indomethacin (Sigma-Aldrich) was dissolved in
polyethylene glycol/Tween 20 (Sigma-Aldrich) (95:5 v/v)
at a concentration of 0.4 mg/mL, then, diluted to 1:200 or
1:100 in drinking water to have 2 ug/mL and 4 ug/mL. The
drinking water was changed twice a week.
Tissue preparation for GALC assay
Tissues from treated and untreated mice were removed
immediately after carbon dioxide euthanasia. The tissues
were immediately homogenized in distilled water using a
Polytron apparatus (Brinkmann Instruments, Westbury,
NY, USA) or frozen quickly and stored at −80°C. Protein
concentration was determined following the method of
Lowry et al.34 GALC activity was measured using [3H]
galactosylceramide substrate, according to our published

method.35 GALC activity was expressed as nmol substrate
hydrolyzed/h/mg protein.
Behavioral studies
Treated mice were weighed and examined for any signs
of tremor, weakness, or gait disturbance daily during
weekdays. Some of these mice were subjected to evaluation
of their walking pattern and capability to hang upside
down from a wire screen.
Walking pattern
A blind tunnel made from a polyvinyl chloride pipe with
34 cm length, 4 cm wide, and 3 cm high was used to record
mice footprints. The front paws of the mice were dipped
in nontoxic red food color, and back paws in blue food
color. The mouse to be evaluate was placed at one of the
tunnel’s end on a blank paper so that it could walk down
the tunnel towards the light source. The piece of paper
with the colored paw prints was retained for comparative
analysis. An 80-day-old normal mouse and 42-day-old
untreated affected mouse were used as the controls.
Wire hanging test
Hanging test was used to assess strength and coordination.
The mouse was placed on top of a wired mesh that was
slowly turned over and maintained horizontally 35 cm
above a thick layer of soft bedding. The length of time
until the mice fell from the wire was recorded. Each
testing consisted of three trials with one-minute intervals
from which the timing scores were averaged. The ability
to hang upside down and move around for 90 seconds
was considered normal. Wild-type mice of different ages
were able to hang and move around for at least 90 seconds.
Untreated twi mice were unable to hang for any length of
time after 25 days of age.
Immunohistochemistry
Frozen brain sections were thawed at room temperature and
fixed for 15 minutes in freshly made 4% paraformaldehyde
(PFA)/PBS. These tissues were permeabilized with 0.5%
Triton X-100 for 10 minutes then treated with blocking
reagent from Vector Laboratories (Burlingame, CA) for one
hour. Tissues were then incubated with the rat anti-CD68
(BioRad, Hercules, CA) or mouse anti-GFAP (Millipore,
MA, USA) for 90 minutes at room temperature to label
macrophages/microglia and astrocytes. The targeted
antigens were visualized by incubating the sections with
the secondary anti-rabbit or anti-rat antibodies (Alexa
488 from Molecular Probes, Eugene, OR, USA) for 2
hours at 25°C. The immunostained slides were mounted
with Vectashield mounting medium containing DAPI
(Vector Laboratories, Burlingame, CA, USA) as a nuclear
marker. Although coronal sections from the entire brain
were monitored, most sections studied were from the
cortex area.
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Statistical analysis
Survival analysis was performed using GraphPad Prism 7.0
software (GraphPad Software Inc., San Diego, CA, USA).
The survival curves were analyzed using the log-rank
(Mantel-Cox) test. (* P < 0.05, ** P < 0.01, *** P < 0.001,
**** P < 0.0001).
Results
Evaluating the effects of treating twi mice with BM cells
from wild-type and heterozygous mice plus AAVrh10mGALC
The current belief about the role of BM cells in the
treatment of twi mice and human KD patients is that
these cells supply some GALC activity to the central and
peripheral nervous system (CNS and PNS) in addition to
their role in preventing neuro-inflammation. We found
this to be in contrast with our recent findings when BM
cells from heterozygous donors were used in combination
with gene therapy.29 Treating mice with BM cells from
wild-type donors and a 1X viral dose (4 ×1013 gc/kg)
results in a longer lifespan compared to mice receiving the
same viral dose and BM cells from heterozygous mice. In
addition, the survival rate of mice treated with BM cells
from heterozygous mice along with a 1X viral dose, is
comparable to the survival rate of the mice treated with
BM cells from wild-type mice but receiving half of the
viral dose (2 × 1013 gc/kg) (Fig. 1). Such findings show the
importance of GALC activity delivered by BM cells in the
twi mouse treated with combined therapy. Studies have
shown no significant histological or behavioral differences
between wild-type and heterozygous mice although
heterozygous mice may have decreased ability to repair
myelin following treatment with cuprizone.36, 37
We examined the GALC activities of the enriched BM
cells from wild-type and carrier mice. The overall GALC

Fig. 1. Comparison of the survival outcomes from twi mice receiving
1X viral dose (4 x 1013 gc/kg) plus BM cells from wild-type mice and twi
mice receiving the same viral dose but BM cells from heterozygote mice.
Another group of twi mice received BMT from wild-type mice but half of
the viral dose (2 x 1013 gc/kg). While the survival curves of the treatment
groups using ½ viral dose or BM cells from carrier mice are not significantly
different from each other (p=0.9999), the survival curves of these two
groups are significantly different from the survival curve of mice receiving
1X viral dose and BM cells from wild-type mice (P < 0.001and P < 0.0001
respectively).
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activity of these cells was much higher than expected. As
Table 1 shows the mean GALC activity measured in BM
cells from wild-type mice, prepared as they are routinely
prepared for BMT, was 4.4 nmol/h/mg protein, ranging
between 3.0 and 6.2 nmol/h/mg protein. It was also the
highest GALC activity of all other organs examined in
these mice, except for the kidneys where the mean GALC
activity was 7.8 nmol/h/mg protein. The average GALC
activity measured in BM cells of the heterozygous mice
was 2.1 nmol/h/mg protein about half of the values from
wild-type mice, as expected (Table 1).
BM cells used for GALC assays were prepared as
described in Materials and Methods. We also assayed
GALC activity of differentiated monocytes/macrophages
from wild type mice that were prepared according to the
method described by Wagner et al.33 GALC activity of
these cells after being in differentiation media for 5 and 8
days was 8.4 and 10.1 nmol/h/mg protein.
Effect of increased viral dose in gene therapy treatment
alone
Previously, we reported the critical role of viral dose in
combinational therapy of twi mice.29 Here, we report the
results of increased viral dose without BMT.
Survival, weight gain, and strength
Fig. 2A shows the extension of the survival of twi mice
as the viral dose increases. Using our initially published
1X viral dose alone the median survival age was 72 days.
The median survival is 351 days when that viral dose is
combined with BMT, clearly showing the synergistic effect
of this combination. However, increasing the viral dose 4X
without BMT raised the median survival age to about 180
days. A 10X viral dose without BMT increased the median
survival age to 280 days without any apparent toxicity.
Longest living mouse treated with a 10X viral dose at
PND10 was sacrificed at age 430 days.
Body weights of the treated mice have been monitored
as an indicator of general health. Fig. 2B shows the growth
and weight gain of the differently treated mice compared
to the untreated affected mice and wild-type mice. While
there is a significant difference in weight gains of the mice
treated with a combination of 1X AAV plus BMT compared
to wild-type mice (P<0.0001), there is no significant
difference between the twi mice receiving 10X AAV alone
compared to wild-type mice. The lower body weights in
the mice receiving combined treatment likely reflect the
effects of the busulfan used for myelosuppression.
A hanging and grip test, an indicator of strength and
coordination, was measured in wild-type mice, untreated
twi mice and affected mice treated with 10X AAVrh10mGALC as described in Materials and Methods. Untreated
twi mice have impaired motor function and are unable to
complete any hanging test after 3-4 weeks of age. However,
mice treated with a high viral dose alone, tested between
250 and 300 days of age, did as well as the wild-type mice
(Fig. 2C). These mice were able to hang on the inverted
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Table 1. GALC activity of different tissues from wild-type and heterozygous mice

Mice age

BM

70-d
80-d
120-d
80-d
150-d
110-d
Mean values

3.0
3.7
4.3
4.2
5.0
6.2
4.40

30-d
45-d
150-d
150-d
218-d
Mean values
* nmol/h/mg protein.

1.7
2.1
3.1
2.0
1.8
2.14

Brain
Cereb
SC
SN
Liver
GALC activity*of different tissues from wild-type mice
1.0
0.7
0.3
0.4
1.1
0.8
1.0
0.8
0.7
1.6
1.7
0.8
1.0
0.8
1.5
1.5
NA
NA
NA
NA
0.6
NA
NA
NA
NA
1.8
NA
NA
NA
NA
1.23
0.83
0.70
0.63
1.36
GALC activity*of different tissues from heterozygote mice
1.2
0.8
0.8
0.8
2.1
0.9
1.0
0.7
1.0
1.3
1.0
0.9
0.6
0.3
0.9
0.7
0.5
0.5
0.1
0.9
0.5
0.6
0.1
0.03
1.7
0.86
0.76
0.54
0.44
1.38

screen for at least 90 seconds, the maximum time allowed
for wild-type mice.
Physical appearance and behavior
All mice treated with a high viral dose alone had normal
appearance compared to wild-type mice, with no tremor
or twitching. Some presented mild wobbling at terminal
age or about a week before death. Mice receiving BMT
alone or BMT plus viral therapy show side effects probably
from the busulfan, including ruffled fur and smaller size.
The mice treated with 10X viral dose alone presented with
shiny, black coats similar to wild-type mice in addition
to normal body weight. Fig. 3A shows one such treated

Heart

Muscle

Kidney

0.4
3.4
0.6
NA
NA
NA
1.46

0.2
0.8
0.4
NA
NA
NA
0.46

9.0
6.5
6.2
8.9
8.4
8.0
7.83

0.4
1.3
0.2
0.2
0.1
0.44

0.4
0.8
0.4
0.7
0.6
0.58

3.4
3.2
2.7
2.5
2.95

mouse with two mice that were treated with BMT plus
viral therapy. Mice treated with the higher viral dose alone,
demonstrated normal behavior for almost their entire
life. This included continuous exploratory movements,
climbing the walls of the cage, and having a normal walking
pattern. Fig. 3B compares the gait pattern of a 260-day-old
mouse treated with 10X viral dose alone to an 80-dayold wild-type mouse and an untreated 42-day-old twi
mouse. Another major drawback of BMT in the treatment
of twi mice is the gonadotoxicity of busulfan and other
myeloablative agents used in the BMT procedure causing
infertility in male and female mice.38 Similar findings have

Fig. 2. Comparing various treatments of twi mice for survival, weight gain and strength. (A) Survival of twi mice treated with AAVrh10 alone at different doses
compared to mice treated with combination therapy and untreated mice. Between 1X and 10X viral dose the survival was highly significant (P < 0.0001).
Comparing 10X alone and 1X + BMT survival was much less significant (P < 0.05). (B) Weighs of the mice treated with 10X AAVrh10 alone (n=9), 1X + BMT
(n=16), untreated affected (n=9) and wild type mice (n=4). (C) Hang time of mice treated with 10X AAVrh10 alone (n=2) tested between 250 and 300 days
compared to untreated affected and wild type mice.
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been reported in human patients receiving HSCT.39 Male
and female affected twi mice treated with a high viral dose
alone maintain their full fertility, delivering several litters
of all affected pups (Fig. 3C). The maturity age and the size
of the litters are comparable to wild-type mice40 (Fig. 3D).
Pathological assessment
Antibodies against CD68, a marker of inflammation, and
glial fibrillary acidic protein (GFAP) are used to compare
the brain sections of mice treated with 10X viral dose to
80-day-old wild-type mouse and 42-day-old untreated
twi mouse (Figs. 4 and 5). In contrast to the untreated twi
mouse, the brain sections of the 90-day-old and 76-dayold AAV-treated mice are free of activated microglial/
macrophages and are comparable to the wild-type mice
(Fig. 4). In Fig. 5, the sections from the same mice stained
with the anti-GFAP antibody are shown. As shown in Fig.
5B, the untreated twi mouse demonstrates an increased
number of hypertrophic reactive appearing astrocytes.
The astrocytic densities of the 90-day-old and 76-day-old
mice treated with 10X viral dose are comparable to the
wild-type mouse (Fig. 5A).
Ability of AAVrh10 to transduce certain tissues including
BM cells following iv injection
We measured the GALC activity in certain tissues,
including BM cells, from twi mice treated with iv gene
therapy alone or gene therapy combined with BMT (Table
2). BM cells from twi mice treated with 10X AAVrh10mGALC alone exhibit GALC activity as high or higher
than mice treated with BMT plus 1X and 4X AAVrh10-

mGALC. GALC expression in these cells could be detected
48 hours after viral injection and remains persistent during
the lifespan of the virally treated mice. To our knowledge,
no published study has described in vivo transduction
of BM cells by any AAV vector. However, several ex vivo
studies using different AAV serotypes including AAV1
and AAV6 have shown a weak transduction of BM cells
in culture.41-44 When BM cells from heterozygous mice
are used for transplantation with the 1X viral dose, the
measured GALC activity in nervous tissues was about half
of the activity measured when BM cells from wild type
mice were used with 1X viral dose (Table 3). The activity
measured is similar to the activity when BM cells from
wild type mice were used with ½X viral dose.
Ability of AAVrh10-mGALC to transduce BM cells in
vitro
Following the detection of the in vivo transduction of BM
cells after iv injection of AAVrh10-mGALC, the question
was whether such ability could be demonstrated in BM
cells in tissue culture. To this end, the harvested BM cells
from twi mice were cultured in monocyte isolation media
(see Materials and Methods). Under such conditions, BM
cells differentiate towards the monocyte/macrophage
state.33 The transductions were done by adding 3 x 1010 gc/
mL of AAVrh10-mGALC to the medium and keeping them
at 37o C in a cell-culture incubator for several days. The
success of the transduction was determined by evaluating
the GALC activity of the cells at different time points.
Increased GALC activity of BM cells could be detected 48

Fig. 3. Effects of various treatments on physical appearance, gait and fertility. (A) The physical appearance of a mouse treated with the 10X viral dose (middle)
is compared to age-matched mice (250-days old) treated with 1X viral dose + BMT. While the mice receiving combined therapy are smaller in size and have
grey fur, the mice treated with the higher viral dose alone have a normal appearance and a normal coat. (B) Footprints of an 80-day-old wild-type mouse (a)
and a 42-day-old untreated affected mouse (b) and a 260-day-old mouse treated with 10X viral dose (c). (C) The second litter resulting from the mating of
affected mice treated with 10X viral dose only. All pups are affected since both parents are genetically homozygote for the twi mutation. (D) Reproductive age
and litter size of female mice treated with 10X viral dose compared to wild-type mice.
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Fig. 4. Staining of activated microglia/macrophages in CNS. Brain sections
from the 90-day-old (image C) and 76-days-old (image D) twitcher mice
treated with high viral dose (4x 1014 gc/kg) only are compared to the
42-day-old untreated twitcher (B) and 80-day-old wild-type mice (A). All
images are from PFA-fixed frozen sections stained with CD68 antibody.
No CD68-positive cells were detected in virally treated twi mice (original
magnification ×400).

Fig. 5. Astrogliosis. All images are from PFA-fixed frozen sections
stained with anti-glial fibrillary acidic protein (GFAP) antibody that detects
astrocytes. Image (A) is from a 80-day-old wild-type mouse, image (B)
from 42-day-old untreated twi, image (C) and (D) from the 90-day-old
and 76-day-old mice respectively treated with 10X viral dose (all original
magnifications are ×400). As shown in images (C) and (D), the astrocyte
distribution is comparable to the wild-type mouse.

hours after transduction and continued to increase with
time. The GALC activity of the transduced BM cells from
twi mice could reach as high as 23.0 nmol/h/mg protein
after being in culture for 5 days and 46.5 nmol/h/mg
protein after being in culture for eight days. This may be
the result of the continuous GALC expression or possibly
due to expressed GALC being taken up from the cultured
media according to the cross-correction phenomena
reported earlier.45

the inflammation by delivering multiple anti-inflammatory
cytokines. However, as HSCT/BMT comes with undesired
side effects, we were interested to see if a safe and similarly
effective option could be found to replace the current
methodology. To this end indomethacin, a well-known
non-steroidal anti-inflammatory drug was chosen to
evaluate its potential in eliminating neuro-inflammation
and slowing disease progression in combination with
gene therapy. In a comparative study of several nonsteroidal anti-inflammatory drugs, indomethacin was
found to decrease the levels of several factors involved in
inflammation.22 Therefore, following iv injection of a 1X
viral dose on PND10, indomethacin was also supplied in
the drinking water with a concentration of 2 ug to 4 ug/

Effects of anti-inflammatory drugs on the progression of
the disease
Given that neuro-inflammation is a component of KD,
HSCT has been recognized as an effective option to lower
Table 2. GALC activity* in certain tissues from mice treated by different methods

Mice treatment**

Brain

Sciatic nerve

Heart

BM cells

BMT + 1X AAV

0.9, 1.4

1.3, 23.0

470.2, 553.7

13.9, 19.8

BMT + 4X AAV

3.0, 3.5

1.8, 4.6

441.0, 515.4

12.1, 13.7

10X AAV only

2.3-5.9

8.6-18.8

488.6-626.9

15.8-44.2

Wild-type

0.6-1.8

0.4-0.8

0.4-3.4

3.0-6.2

0-0.1

0.1-0.2

0-0.2

0-0.1

Untreated twi

* nmol/h/mg protein.
** Two mice analyzed in “BMT + 1X AAV” group were at PND218 and 362, two mice in group “BMT + 4X AAV” were at PND105 and 341 and five mice
in group “10X AAV alone” were at PND37, 54, 90, 111 and 150.

Table 3. GALC activity in nervous tissues based on BM donor type and viral dose

Treatment

Average of GALC activity* n=6-13

BM donor

Viral dose

Brain

Cerebellum

Sciatic Nerve

Wild-type mice

1X viral dose

1.7

1.6

5.9

Wild-type mice

1/2X viral dose

0.8

1.0

2.0

Wild-type mice

No viral injection

0.9

1.0

1.4

Heterozygote mice

1X viral dose

0.8

1.1

2.7

* nmol/h/mg protein.
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mL starting on PND14 and continued for 4 weeks. No
tangible positive result was obtained from the total of six
mice treated this way. Treated mice lived between 54 and
67 days, which was similar to the treatment with a 1X viral
dose alone.
BMT using BM cells with supra-normal GALC activity
Multiple attempts at transplanting in vivo-transduced
BM cells expressing supra-normal GALC activity failed
engraftment. The isolated BM cells from twi mice that had
been treated with a 10X dose of AAV vector had GALC
activity between 16 and 44 nmol/h/mg protein (Table 2).
This is well above GALC activity in BM cells of wild type
mice (Table 1). Transplantation failure was previously
reported by Gentner et al46 using high GALC-expressing
BM cells following in vitro transduction by a lentiviral
vector. As the transplantation failed, they concluded
that higher than normal GALC activity must be toxic
for hematopoietic stem cells and early progenitor cells.
However, following the iv injection of 10X AAVrh10mGALC, the GALC activity in BM cells is much higher
than BM cells from wild type mice (Table 2) yet mice
treated in this manner live much longer than twi mice
treated by BMT or with 1X AAVrh10-mGALC alone. This
indicates that their BM is functioning normally although
it has very high GALC activity.
Discussion
KD is caused by the deficiency of GALC activity resulting
from mutations in the GALC gene. Several animal models,
including mice, dogs, and rhesus monkeys, have also
been identified.6-8 The mouse model of this disease has a
mutation causing a premature stop codon in the GALC
gene.30 Mice homozygous for this mutation usually die
between 35 and 45 days.
BMT treatment of twi mice has resulted in increased
lifespan as reported by several studies.23-26,28 Some authors
believe that the effectiveness of BMT is mostly due to
the ability of the BM cells to deliver GALC activity to
the critical tissues,25-27 while others consider their antiinflammation properties as an additional beneficial
factor.20,27,28 Adding gene therapy to BMT has resulted in a
much better outcome as reported by us and others.10,19,20,27-29,
47
However, the mechanism of such synergistic effect has
not been clearly understood. As discussed below, the data
presented in this paper suggest that HSCT/BMT may
not be necessary for successful treatment of twi mice or
Krabbe patients if a high dose of viral vector alone is timely
delivered to the critical tissues. This will result in sufficient
GALC expression in CNS before the accumulation of toxic
metabolites that will trigger neuro-inflammation.
Timing of the pathological damages causing inflammation
in the CNS of twi mice
Twi mice are indistinguishable from wild-type littermates
until PND20-21 and have similar immune response
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capability as wild-type mice.48 Neurologic features
including tremors and ataxic gait appear around day
20.49 Evidence of hypomyelination in the PNS also
has been reported around PND15-20.50 The earliest
changes in microglial morphology was not seen until
two weeks of age.51 Therefore, twi mice treated with
BMT may benefit from the anti-inflammatory role of
the infiltrated macrophages in the CNS only when the
disease has progressed. The same may be true in affected
human patients. Supplying enough GALC activity at the
earlier time, when the mouse or human patient is presymptomatic, could prevent disease progression and avert
CNS inflammation (Figs. 4 and 5). This can be done by
GALC-expressing macrophages produced by HSCT/BMT
or by transducing endogenous macrophages by other
strategies such as gene therapy. The advantage of in vivo
virally-transduced macrophages is that they can rapidly
deliver high GALC activity to degrade myelin debris and
prevent globoid cell formation.
As noted in the Results section, the addition of
indomethacin in the drinking water did not have any
synergistic effect when these mice were also treated with
gene therapy. These experiments may indicate the absence
of neuro-inflammation at the time of the treatment if
sufficient GALC is delivered to the CNS. Therefore, in
addition to the anti-inflammatory role of HSCT/BMT
discussed in our earlier study,22 BMT also supplies some
GALC activity when combined with viral gene therapy.
Hence, with earlier delivery of sufficient GALC activity
there may be less myelin degradation, neuro-inflammation
and globoid cell formation.
We have recently shown that a single iv injection of
AAVrh10-mGALC combined with BMT can result in
comparable outcomes when implemented between
PND10 and PND18 in twi mice.29 The most consistent
outcomes in our experiments are seen when mice are
treated between PND10 and PND15. A similar presymptomatic period to start treatment may be available
for human patients.
In vivo transduction of BM cells
Table 2 shows the increase in GALC activity of BM cells
following iv injection of AAVrh10-mGALC with or
without BMT. The GALC activity in BM cells of twi mice
treated with 10X AAV alone is as high or higher than BM
cells from twi mice treated with BMT plus 1X or 4X AAV.
This could indicate that BMT is not needed to deliver
GALC activity to nervous tissues. While it takes about
seven days for the macrophages to be differentiated and
infiltrated in the CNS following BMT,52 it takes less time
for endogenous BM cells to be transduced following iv
viral injection and to reach the CNS after differentiation.
Avoiding the adverse side effects of the myeloablative
regimens
The undesirable side effects of the myeloablative
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regimens required for HSCT/BMT are significant. In
our experiments, all of the mice treated with busulfan
before BMT have lower body weight, infertility, and
depigmentation of their fur (Fig. 3). Similar side effects
of busulfan treatment have also been reported by Yeager
et al.53 Busulfan and cyclophosphamide are currently
the most widely used in the myeloablative regimen of
allogeneic stem cell transplantation in human patients. In
addition to side effects of these drugs, human transplant
recipients can also suffer from varying degrees of graftversus-host disease.54 As can be seen in Figs. 2 and 3 mice
treated with high dose gene therapy alone have the same
weight, normal appearance and fertility as wild type mice.
Therefore, the use of gene therapy alone at a sufficient
dose and before neuro-inflammation has occurred may
replace the need for blood stem cell transplantation.
Delivery of GALC activity to twi mice via gene therapy
versus BMT
In the present study, we measured the GALC activity in
certain tissues, including BM cells, in wild type mice,
untreated twi mice as well as twi mice treated with
combined therapy and 10X viral gene therapy alone (Table
2). Clearly, the BM cells of twi mice treated with gene
therapy have higher GALC activity than wild type mice.
Our recent publication29 showed that mice treated
with BM cells from heterozygous mice plus 1X viral
dose had decreased survival compared to when BM cells
from wild-type mice were used. This suggested that BM
cells from wild type mice were delivering more GALC
activity to critical tissues. This is borne out by the data
shown in Table 3. While the anti-inflammatory cytokines
delivered by BM cells from wild-type and heterozygote
mice should be similar, the GALC activity of BM cells
from heterozygote mice is about half of the value from
wild-type mice (Table 1). As shown in Fig. 1 the survival
curve of these mice is comparable to the survival of the
mice receiving BMT from wild-type mice but injected
with1/2X viral dose. The GALC activity measured in the
CNS of mice treated with a 1X viral dose plus BM cells
from wild-type mice is higher than in mice treated with
BM cells from wild type mice alone and mice treated
with 1X viral dose and BM cells from heterozygous mice
(Table 3). Therefore, GALC activity in nervous tissues of
twi mice treated with combined therapy comes from both
the viral vector transducing endogenous brain cells and
macrophages recruited from the blood after BMT.
There appeared to be a failure of engraftment into
twi mice when isolated BM cells expressing high GALC
activity following iv AAVrh10-mGALC injection were
used for transplantation. As mentioned in the Results
section, similar transplantation failure was also reported
by Gentner et al46 when the authors used lentvirallytransduced BM cells with supra-normal GALC activity.
The authors’ interpretation was that higher than normal
GALC activity may be toxic for hematopoietic stem cells

and early progenitor cells. Suppressing GALC expression
in these cells via incorporation of the miR-126 sequence
in the viral vector resulted in a successful transplantation.
However, average survival with this treatment was only 88
days. In our experiments, all of the treatment approaches
involving iv injection of AAVrh10-mGALC have resulted
in higher than normal GALC expression in BM cells of
the treated mice (Table 2) with no apparent toxicity. The
reason for unsuccessful transplantation using BM cells
over-expressing GALC activity may be caused by the
bone structure and BM niche composition. As reported
by Katayama and Frenette,55 galcer, the main substrate
for GALC enzyme, plays an essential role in BM niche
structure and function. These authors have shown that
galcer is crucial in establishing lymphoid-supportive
niches and differentiation of lymphoid precursor cells in
the BM. The synthesis of galcer is initiated by the addition
of UDP-galactose to ceramide in a reaction catalyzed by
UDP-galactose: ceramide galactosyltransferase (CGT).
As shown by Katayama and colleagues, CGT-deficient
mice lacking galcer exhibit aberrant nerve conduction
and disturbed BM niche function.56 In the case of
supra-normal GALC expression, destruction of the BM
niches via hydrolyzing BM galcer, could affect the BM’s
engraftment. Interestingly, blocking GALC expression
by “stem cell-specific miRNAs” enabled transplantation,
not by preventing the cellular apoptosis caused by GALC
toxicity, but by safeguarding the BM niches’ functionality
and allowing engraftment.46
Given that the mice treated with a 10X viral dose alone
benefitted from an extension of healthy and active life, one
can reasonably conclude that any treatment strategy must
deliver an adequate amount of missing enzyme to the
CNS and the PNS before pathology has occurred. Unlike
the mice treated with a combination of gene therapy and
BMT, these mice are fertile and capable of delivering
several litters with up to nine pups in each litter. All of
these pups are genetically affected when both parents are
affected and treated with gene therapy alone.
It is noteworthy that current gene therapy research
suggests that AAVrh10 and AAV9 are the most efficient
viral vectors in crossing the BBB.57 However, following
systemic injection an overwhelming number of viral
particles are trapped in peripheral organs and only a small
fraction may reach the CNS and PNS. In the absence of
an ideal viral vector with higher capability of crossing
the BBB and transducing the critical cells, one practical
way of eliminating BMT is by raising the viral dose. As
demonstrated in this study, the iv injection of 4 ×1014 gc/kg
body weight of AAVrh10-mGALC, has been tolerated very
well in the mouse model of GLD with very encouraging
outcomes and no apparent evidence of toxicity. Perhaps
the viral dose may be increased even further without
any toxicity. In support of the presented data, other
recent publications have shown significant correction of
neurologic disease using gene therapy alone without BM
BioImpacts, 2021, 11(2), 135-146
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cell transplantation. When high dose AAV9 is injected
intrathecally at an early time point, there is a significant
extension of life in the dog model of KD without the need
for BMT.58 Previously, a single iv injection of rAAV vector
containing aspartoacylase cDNA alone at an early age,
showed significant effectiveness in treating the mouse
model of Canavan disease.59 Also, a single iv injection of
a self-complementary AAV9 vector expressing the Hexb
cDNA in Sandhoff disease mice has also been shown to be
safe, prevent disease development and result in a normal
lifspan.60 However, some recent studies have documented
the deaths of patients who received high-dose AAV gene
therapy.61 It should be noted that the patients who died
following high-dose gene therapy had different diseases
and pre-existing liver disease and were treated with
different AAV vectors. While some pathological changes
were documented in the livers of twi mice treated with
combined BMT plus iv AAVrh10-mGALC, there was no
evidence of neoplastic changes.29 In conclusion, it appears
that AAVrh10-mGALC injected iv at a high enough dose
before significant pathology has taken place has the ability
to deliver GALC activity to the CNS and PNS without the
need for BMT/HSCT and to extend life without the side
effects of HSCT. With further study, it may be possible to
safely treat human patients with KD using only viral gene
therapy.
Conclusion
Previous studies have shown that BMT together with a
single intra-venous injection of AAVrh10-GALC results in
a much better outcome than either treatment alone in twi
mice. Those studies also showed that timing and dosing
is critical to a successful outcome. It has been postulated
that BM cells provide some GALC activity to many tissues
as well providing an anti-inflammatory component to
the treatment. The addition of the viral vector results in
higher GALC activity being expressed in many tissues,
including the central and peripheral nervous systems,
leading to much improved myelination and greatly
extended life in treated mice. As the drugs used for myelosuppression before BMT have significant side effects, it
was considered that the early injection of high dose viral
vector alone could prevent the inflammatory component
of this disease and therefore eliminate the need for BMT.
The results show that when a viral dose of 4 ×1014 gc/kg is
injected at PND10 there is a significant extension of life,
about 7 times that of untreated mice, normal appearance
and strength and normal fertility. In addition there is
much less activated microglia/macrophages indicating less
inflammation and less astrogliosis. These studies indicate
that it may be possible to treat patients with KD with high
dose viral vector alone without the need for blood stem
cell transplantation and the drugs used in that therapy.
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Research Highlights
What is the current knowledge?
√ KD is an autosomal recessive lysosomal disorder.
√ KD is caused by mutations in the GALC gene.
√ Low GALC activity causes defective myelination in the
peripheral and central nervous systems.
√ HSCT in pre-symptomatic human patients is the only
effective treatment at this time.
√ The twi mouse is a useful model to study pathogenesis and
treatment of KD.
√ BMT has shown to have a synergistic effect when combined
with other treatment strategies such as gene therapy in the
animal models.
What is new here?
√ Intra-venous (iv) injection of AAVrh10-mGALC gene alone
at a sufficient viral dose and before neuro-inflammation has
occurred resulted in extended normal life in twi mice.
√ Iv AAvrh10 gene therapy alone raised GALC activity in
heart, brain, sciatic nerve and BM cells.
√ BM cells with high GALC activity from in vivo transduction
were not successful in treating twi mice when used for BMT.
√ With further study, this approach may eliminate the need
for HSCT and its side effects in human patients.
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